Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avecia and Illumigen to co-develop RNA virus product
Under the agreement, terms of which have not been disclosed, Avecia will carry out development work to optimize the drug manufacturing process and conduct initial cGMP manufacture of
Under the agreement, terms of which have not been disclosed, Avecia will carry out development work to optimize the drug manufacturing process and conduct initial cGMP manufacture of
The phase II trial is evaluating the efficacy and safety of combining therapy with the monoclonal antibody rituximab and the cytokine sargramostim compared to treatment with rituximab alone.
Patent claims were brought by EEMSO over the Companion80 product, an inflammatory treatment manufactured by Iomed which uses iontophoresis technology. “It was essential that we aggressively defend against
The trial evaluated the efficacy and safety of Albuferon in combination with ribavirin in patients with chronic hepatitis C. The data suggested that Albuferon may offer efficacy at
The study is designed to evaluate Resten-MP delivered intravenously via microparticle technology, in conjunction with placement of one or more bare-metal stents. Resten-MP is a treatment designed to
The company submitted a new drug application in January 2006, seeking to market Zenvia for the treatment of involuntary emotional expression disorder (IEED) in patients with neurologic diseases
This orphan medicinal product status grants CytRx market exclusivity in the European Union for 10 years in the event that arimoclomol receives marketing approval. The status provides for
The study is designed to determine the maximum tolerated dose and to evaluate the safety and efficacy of BZL101. The company expects to begin patient enrollment early in
The application will be for the use of Advexin p53 therapy for the treatment of Li-Fraumeni Syndrome (LFS). LFS is a genetic disorder characterized by inherited mutations in
Licensed in 2003 from EpiCept Corporation for North America, the product was in phase II clinical development. Adolor expects to transition the program to EpiCept by the end